[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345025-105":59,"doc-detail-345025-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nicotinamide-for-skin-cancer-chemoprevention-the-jury-was-out-and-still-is","Nicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still is","","Nicotinamide is promoted as a low-cost chemopreventive agent for non-melanoma skin cancer, yet evidence remains mixed. A retrospective analysis of 33,000+ US veterans reported a 14% reduction in overall skin cancer risk and a 22% reduction in cutaneous squamous cell carcinoma, especially when started early. This critical appraisal examines key limitations including unmeasured confounding, immortal time bias, exposure misclassification, flexible modeling, and limited external validity, comparing the study with systematic reviews from 2022–2023 and emphasizing caution before routine adoption.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nicotinamide-for-skin-cancer-chemoprevention-the-jury-was-out-and-still-is/345025/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nicotinamide-for-skin-cancer-chemoprevention-the-jury-was-out-and-still-is/345025.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the recent large retrospective cohort study report about nicotinamide?","Question",{"text":112,"@type":113},"It reports a 14% reduction in overall skin cancer risk and a 22% reduction in cutaneous squamous cell carcinoma with nicotinamide use, with the greatest benefit when started early.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What internal validity concerns are raised about the study?",{"text":117,"@type":113},"Concerns include lack of protocol registration, risks of post-hoc selective reporting, and the need for more appropriate reporting frameworks for routinely collected data, such as STROBERECORD.",{"name":119,"@type":110,"acceptedAnswer":120},"Why does the article advise caution before routine clinical adoption of nicotinamide?",{"text":121,"@type":113},"The appraisal concludes current evidence does not yet confirm chemopreventive efficacy and highlights methodological limitations such as confounding, immortal time bias, exposure misclassification, flexible modeling, and limited external validity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345025,1790386387,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","American Journal of Clinical Dermatology (2026) 27:209–215  \n[https://doi.org/10.1007/s40257-025-01005-y](https://doi.org/10.1007/s40257-025-01005-y)  \nNicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still is  \nEugene Tan1 · Hywel C. Williams2  \nReceived: 4 November 2025 / Accepted: 14 December 2025 / Published online: 8 January 2026 © The Author(s) 2026  \nAbstract  \nNicotinamide has been widely promoted as a low-cost safe chemopreventive agent against non-melanoma skin cancer. A recent large retrospective study of more than 33,000 US veterans reported a 14% reduction in overall skin cancer risk and a 22% reduction in cutaneous squamous cell carcinoma with nicotinamide use, with greater benefit observed when initiated early. This critical appraisal identifies key methodological limitations of that study, including unmeasured confounders, immortal time bias, exposure misclassification, flexible analytical modelling and limited external validity. The findings are discussed in the context of two recent systematic reviews (2022 and 2023) to provide a balanced appraisal of the evidence and clarify whether nicotinamide should be recommended in routine practice. Current evidence does not yet confirm the chemopreventive efficacy of nicotinamide. Caution is warranted before its widespread clinical adoption—the jury, as it stands, is still out.  \n* Eugene Tan [eugene.tan1@unsw.edu.au](eugene.tan1@unsw.edu.au)  \n1 School of Clinical Medicine (St Vincent’s Campus), UNSW Medicine, Sydney, NSW, Australia  \n2 Centre of Evidence-Based Dermatology, Lifespan and Population Health, School of Medicine, University of Nottingham, Nottingham, England  \nGraphical Abstract  \nAmerican Journal of Clinical Dermatology  \nNico􀀛namide for Skin Cancer Chemopreven􀀛on – The Jury Was Out & S􀀛ll is Eugene Tan & Hywel C. Williams  \nThis graphical abstract represents the opinions of the authors. For a full list of declara􀀊ons, including funding and author disclosure statements, and copyright informa􀀊on, please see the full text online.  \n1 Introduction  \nNicotinamide has attracted considerable attention as a safe and low-cost chemopreventive agent for individuals at high risk of keratinocyte cancer (non-melanoma skin cancer), following the landmark phase III (ONTRAC) trial conducted a decade ago [1]. However, a subsequent trial (ONTRANS) in immunosuppressed solid-organ transplant recipients failed to replicate these benefits, confirming existing critiques of the ONTRAC statistical analyses [2] . Its results were further limited by poor recruitment and premature termination [3] . Despite this negative study and others reporting no significant difference between nicotinamide and placebo,[4–6] enthusiasm for nicotinamide remains high. Some clinicians have incorporated nicotinamide into practice [7]—a nationwide survey of Mohs surgeons found that 76.9% recommend nicotinamide for keratinocyte cancer prevention [8] .  \nMore recently, a large retrospective study has reignited interest in this vitamin [9] . We therefore sought to critically appraise the recent study and contrast it to earlier systematic reviews comparing oral nicotinamide with placebo in highrisk populations, focusing on outcomes of reduced actinickeratoses and/or keratinocyte cancer incidence.  \n2 What Did the Recent Large Retrospective Cohort Study Show?  \nIn this retrospective cohort study of 33,822 veterans with prior skin cancer, oral nicotinamide 500 mg twice daily for at least 30 days was compared with no nicotinamide use to assess its effect on the time to subsequent skin cancer development. Nicotinamide use was associated with a 14% overall reduction in skin cancer risk. This risk reduction was strongest for cutaneous squamous cell carcinoma with a 22% reduction. The benefit was greatest when started after  \nthe first skin cancer (~50% reduction), but diminished with later initiation. Solid organ transplant recipients showed no overall benefit. The authors concluded that nicoti","cbCaifSe1lb4EJXD","https://ap.wps.com/l/cbCaifSe1lb4EJXD","pdf",1178150,"English","# Introduction\n# What Did the Recent Large Retrospective Cohort Study Show?\n# What is the Internal Validity of this Study?","[{\"question\":\"What does the recent large retrospective cohort study report about nicotinamide?\",\"answer\":\"It reports a 14% reduction in overall skin cancer risk and a 22% reduction in cutaneous squamous cell carcinoma with nicotinamide use, with the greatest benefit when started early.\"},{\"question\":\"What internal validity concerns are raised about the study?\",\"answer\":\"Concerns include lack of protocol registration, risks of post-hoc selective reporting, and the need for more appropriate reporting frameworks for routinely collected data, such as STROBERECORD.\"},{\"question\":\"Why does the article advise caution before routine clinical adoption of nicotinamide?\",\"answer\":\"The appraisal concludes current evidence does not yet confirm chemopreventive efficacy and highlights methodological limitations such as confounding, immortal time bias, exposure misclassification, flexible modeling, and limited external validity.\"}]","Nicotinamide for Skin Cancer Chemoprevention: The Jury Was Out and Still is | PDF",1790056259,18,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c0b4d067fe894e0ed4b86ef5919a266.webp",983,1305,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8152f0ab9bf1d2570bd3a5035c104355.webp",982,1304,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/db1761923aab08411fbd542669d44a6f.webp",981,1303,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/afe737a23eeef9234e4fa3f2f2719410.webp",980,1301]